CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
Oral presentation at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the Canadian Cancer Trials Group (CCTG) HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
The INTEGRATE IIa (CCTG GA3) study, a phase III trial evaluated regorafenib for the treatment of patients with advanced gastro-oesophageal cancer (AGOC), has met its primary endpoint of a statistically significant improvement in overall survival of about 30%. The study evaluated the efficacy and safety of regorafenib in patients with AGOC, whose disease has progressed after a minimum of two lines of prior anti-cancer therapy for recurrent/metastatic disease. The safety and tolerability were generally consistent with the known profile of regorafenib.
OV25: A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been closed to accrual. 117 of the planned 414 patients were randomized (80 from Can
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.
The Canadian Institutes of Health Research recently announced the recipients of the Clinical Trials Fund. The Canadian Cancer Trials Group with study lead Dr Elena Elimova at Princess Margaret Cancer Centre were granted $3,744,953 over 3 years to fund the CCTG GA4 study in HER2 overexpressing advanced gastroesophageal adenocarcinoma.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
The entire CCTG team extends a warm welcome to Dr Mariam Jafri who has recently joined us as a Senior Investigator. Dr Jafri was a consultant in Medical Oncology at the University Hospital Birmingham. She has specific expertise in breast cancer, germ cell tumours, sarcoma and Adolescent and Young Adults (AYA) with cancer with particular interest in using genomics to tailor treatment to patients. Dr Jafri completed her oncology specialty training in the West Midlands and Oxford U.K. and two research fellowships which culminated in her receiving a Ph.D. in the molecular biology of cancer.
